Malaysia MDA–HSA Regulatory Reliance 2026

Following our previous update on “Malaysia-Singapore 2025 MOU on Medical Device Regulatory Reliance” published on August 25th 2025, Malaysia’s regulatory authority, the Medical Device Authority (MDA), has announced that it will formally recognize Singapore’s Health Sciences Authority (HSA) as a reference country under its Medical Device Regulatory Reliance Programme.

This confirmation follows the successful six-month pilot implementation conducted from 1 September 2025 to 28 February 2026. Under this 2026 update, medical devices already registered in Singapore may now qualify for conformity assessment in Malaysia via a verification process, benefiting from lower Conformity Assessment Body (CAB) fees and typically shorter review timelines.

Key Updates in the 2026 MDA–HSA Reliance Programme

With the pilot phase successfully completed, MDA will now:

• Formally recognize HSA as a reference authority

• Permit use of Singapore approvals for conformity assessment by verification

• Provide a streamlined regulatory pathway for eligible manufacturers

• Offer reduced CAB fees

• Shorten review timelines in most qualifying cases

This marks the transition of the reliance programme from pilot stage to formal implementation.

Impact on Malaysia Medical Device Registration

Manufacturers holding valid HSA approval may benefit from a more efficient pathway to Malaysia market access.

Key advantages include:

• Lower conformity assessment costs

• Faster time to approval

• Reduced duplication of technical evaluation

• Greater regulatory predictability

Through the verification route, Malaysian CABs may leverage prior HSA assessment outcomes, minimizing the need for full reassessment where appropriate.

Manufacturers must still ensure compliance with Malaysia-specific regulatory requirements, including classification rules, labeling obligations, and post-market surveillance responsibilities.

Eligibility and Compliance Considerations

To qualify under the reliance pathway, manufacturers should:

1. Ensure the device holds valid and active HSA registration.

2. Confirm classification alignment between Singapore and Malaysia frameworks.

3. Prepare complete technical documentation for CAB verification.

4. Coordinate with a Malaysian authorized representative where required.

Final eligibility remains subject to MDA and CAB review.

Regional Regulatory Significance

The formal recognition of HSA as a reference authority demonstrates Malaysia’s growing adoption of regulatory reliance mechanisms. Such frameworks:

• Optimize regulatory resources

• Reduce redundant assessments

• Accelerate patient access to medical devices

• Support ASEAN regulatory convergence

This development reinforces Malaysia’s commitment to efficient, risk-based regulatory systems while maintaining safety and quality oversight.

External References

• Official announcement from MDA Malaysia

Internal References

Learn more about:

• MDA Malaysia Medical Device Registration

• HSA Singapore Medical Device Registration

‍